Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive
Between 1992 and 2012, 871 patients underwent radical nephrectomy; cytoreductive
procedures for RCC were also included.
The role of cytoreductive
surgery in cervical cancer: Is there a benefit of retroperitoneal lymph node debulking in advanced disease?
assemble 33 chapters by a group of gynecology, gynecologic oncology, obstetrics, and other specialists from the US and Canada, who present fundamental and emerging information on individual gynecologic cancers, evidence-based clinical practice guidelines, and the diagnosis, management, and treatment of specific reproductive tract malignancies, as well as a surgical atlas of key and minimally invasive procedures, staging, and advanced cytoreductive
Although clinical complete remissions are obtained in the majority of patients through a combination of cytoreductive
surgery and chemotherapy, relapse remains common.
While controversial, the benefit of secondary cytoreductive
procedures for recurrent epithelial ovarian cancer has been reported in retrospective series (1).
therapy lowered the WBC during follow-up, which was associated with a reduction in its thrombogenic effect; 3.
surgery and intraperitoneal chemotherapy are treatment options for diffuse malignant mesothelioma, whereas most cases of localized malignant mesothelioma are cured by surgical excision.
Treatment has centered on cytoreduction by therapeutic phlebotomy and/or treatment with cytoreductive
pharmaceuticals such as hydroxyurea or [alpha]-interferon.
Some clinical and pathological findings associated with TKI treatment may also require further evidence-based characterization, including non-clear cell histology, sarcomatoid differentiation, the role of cytoreductive
nephrectomy, and the interactions of other drugs with TKIs.
A systematic review on the efficacy of cytoreductive
surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma.
For those of you with a partial remission, my goal is to keep you on path C1, with the hope that you will move toward complete remission, either when our rehabilitation program enables you to return to cytoreductive
therapies or when new conventional therapies become available.